US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Champion Industries, Inc.

0.0200

0.0000

Volume:- -

Turnover:- -

Market Cap:1.12K

PE:0.00

High:0.0200

Open:0.0200

Low:0.0200

Close:0.0200

52wk High:0.0200

52wk Low:0.0001

Shares:55.86K

Float Shares:- -

Volume Ratio:0.01

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

EPS(TTM):-23.0334

EPS(LYR):-23.0334

ROE:-49.45%

ROA:-1.87%

PB:0.00

PE(LYR):0.00

Loading ...

Overview Company News Filings

Apellis Pharmaceuticals Reports Third Quarter 2025 Financial Results

Agios Reports Third Quarter 2025 Financial Results and Provides Business Update

CStone Pharmaceuticals (SEHK:2616): Valuation in Focus After Landmark CHMP Nod and Pipeline Breakthroughs

Simply Wall St.

GSK’s Shingrix Prefilled Syringe Gains Positive CHMP Opinion

Verrica Pharmaceuticals announces CHMP support for Ycanth MAA filing

Verrica Pharmaceuticals Receives Positive Feedback from the European Medicines Agency (EMA) Supporting a Clear Regulatory Path Forward to File for Approval of YCANTH® in the European Union

How Could EMA's Elfabrio Decision Reshape Protalix BioTherapeutics' (PLX) Rare Disease Strategy?

Simply Wall St.

Why Is Protalix BioTherapeutics Stock Falling On Friday?

Benzinga_recent_news

Agios Gets CHMP Backing of Pyrukynd in Thalassemia

Agios’ PYRUKYND® (mitapivat) Receives Positive CHMP Opinion for Adults with Thalassemia

Novartis Scemblix receives positive CHMP opinion for Scemblix

Novartis Scemblix® receives positive CHMP opinion for the treatment of adults with newly diagnosed CML

CStone Pharmaceuticals Gains CHMP Positive Opinion for Sugemalimab in Stage III NSCLC

Cellectar Biosciences Announces European Medicines Agency (EMA) Confirms Eligibility to File for Conditional Marketing Authorization (CMA) for Iopofosine I 131 as a Treatment for Refractory (post-BTKi) Waldenstrom Macroglobulinemia (WM)

Crinetics Announces FDA Approval of PALSONIFY™ (paltusotine) for the Treatment of Adults with Acromegaly

Clinuvel Pharmaceuticals Says EMA Removes Recommended Maximum Dose for Genetic Disorder Drug

MT Newswires Live

Sanofi’s Dupixent Advances in EU with Positive CHMP Opinion

European Advisory Panel Recommends Two AstraZeneca Drugs For Approval

Dr. Reddy’s Receives Positive CHMP Opinion for AVT03 Biosimilar

Dupixent® (dupilumab) to Treat Chronic Spontaneous Urticaria (CSU) Advances in EU with Positive CHMP Opinion

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CHMP/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CHMP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CHMP\",,,,,undefined,":{"symbol":"CHMP","market":"US","secType":"STK","nameCN":"Champion Industries, Inc.","latestPrice":0.02,"timestamp":1773432000000,"preClose":0.02,"halted":0,"volume":0,"delay":15,"changeRate":0,"floatShares":0,"shares":55857,"eps":-23.033406,"marketStatus":"Market Closed","change":0,"latestTime":"03-13 16:00:00 EDT Delay","open":0.02,"high":0.02,"low":0.02,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-23.033406,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1773648000000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"EXPERT","adjPreClose":0.02,"volumeRatio":0.014044951710647027},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CHMP\",,,,,undefined,":{"symbol":"CHMP","floatShares":0,"roa":"-1.87%","roe":"-49.45%","lyrEps":-23.033406,"volumeRatio":0.014044951710647027,"shares":55857,"dividePrice":0,"high":0.02,"amplitude":0,"preClose":0.02,"low":0.02,"week52Low":0.0001,"pbRate":"0.00","psRate":"0.00","week52High":0.02,"institutionHeld":0,"latestPrice":0.02,"eps":-23.033406,"divideRate":0,"volume":0,"delay":15,"ttmEps":-23.033406,"open":0.02,"prevYearClose":0.02,"prevWeekClose":0.02,"prevMonthClose":0.02,"prevQuarterClose":0.02,"fiveDayClose":0.02,"twentyDayClose":0.02,"sixtyDayClose":0.0001},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CHMP\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CHMP\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CHMP\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CHMP\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2579170781","title":"Apellis Pharmaceuticals Reports Third Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2579170781","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579170781?lang=en_us&edition=fundamental","pubTime":"2025-10-30 19:05","pubTimestamp":1761822300,"startTime":"0","endTime":"0","summary":"Generated $459 million in 3Q 2025 revenues, including $178 million in U.S. net product salesReceived 152 new patient start forms for EMPAVELI (pegcetacoplan) in the first two months since launch in C3","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/30/3177251/0/en/Apellis-Pharmaceuticals-Reports-Third-Quarter-2025-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FSGS","LU1242518857.USD","LU1880398554.USD","LU0109392836.USD","LU0823434583.USD","IE0004445239.USD","LU0642271901.SGD","LU2458330169.SGD","BK4573","BK4554","LU1064131342.USD","BK4566","LU1242518931.SGD","LU2054465674.USD","CHMP","LU0979878070.USD","LU1951200564.SGD","LU0823421333.USD","BK4141","LU0823421416.USD","LU0719512351.SGD","BK4575","LU0082616367.USD","BK4534","LU0823434740.USD","LU1852331112.SGD","LU1803068979.SGD","LU2250418816.HKD","LU1988902786.USD","BK4512","LU1951198990.SGD","LU0889565833.HKD","BK4543","EMA","LU0056508442.USD","LU1303367103.USD","IE0009356076.USD","LU1880398471.USD","LU2360106780.USD","IE00B5949003.HKD","LU1861558580.USD","LU0390134368.USD","BK4532","BK4529","LU0127658192.USD","BK4585","LU1316542783.SGD","LU2098885051.SGD","BK4087"],"gpt_icon":1},{"id":"2579114441","title":"Agios Reports Third Quarter 2025 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2579114441","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579114441?lang=en_us&edition=fundamental","pubTime":"2025-10-30 18:30","pubTimestamp":1761820200,"startTime":"0","endTime":"0","summary":"$12.9 million in third quarter PYRUKYND (mitapivat) net revenuesPDUFA goal date for PYRUKYND U.S. sNDA in thalassemia set for December 7, 2025CHMP adopted positive opinion for PYRUKYND in thalassemia;","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/30/3177175/31990/en/Agios-Reports-Third-Quarter-2025-Financial-Results-and-Provides-Business-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EMA","CHMP","GCC","BK4081","BK4087"],"gpt_icon":0},{"id":"2578630717","title":"CStone Pharmaceuticals (SEHK:2616): Valuation in Focus After Landmark CHMP Nod and Pipeline Breakthroughs","url":"https://stock-news.laohu8.com/highlight/detail?id=2578630717","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578630717?lang=en_us&edition=fundamental","pubTime":"2025-10-26 17:25","pubTimestamp":1761470729,"startTime":"0","endTime":"0","summary":"CStone Pharmaceuticals (SEHK:2616) is gaining attention after two key developments: a positive opinion from Europe’s drug regulator for sugemalimab in lung cancer, and fresh data on its early-stage immunotherapy candidates. Investors are watching closely.\nSee our latest analysis for CStone Pharmaceuticals.\nThe recent surge in CStone Pharmaceuticals’ share price, up nearly 158% year-to-date, reflects growing investor confidence on the back of regulatory wins and progress with its immunotherapy...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2616/cstone-pharmaceuticals-shares/news/cstone-pharmaceuticals-sehk2616-valuation-in-focus-after-lan","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2616/cstone-pharmaceuticals-shares/news/cstone-pharmaceuticals-sehk2616-valuation-in-focus-after-lan","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4087","BK1161","LARK","DCF","02616","CHMP","BK1574","BK4211"],"gpt_icon":0},{"id":"2577405845","title":"GSK’s Shingrix Prefilled Syringe Gains Positive CHMP Opinion","url":"https://stock-news.laohu8.com/highlight/detail?id=2577405845","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577405845?lang=en_us&edition=fundamental","pubTime":"2025-10-21 14:23","pubTimestamp":1761027806,"startTime":"0","endTime":"0","summary":"GlaxoSmithKline ( ($GB:GSK) ) has issued an announcement. GSK announced that the European Medicine Agency’s Committee for Medicinal Products for Hu...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/gsks-shingrix-prefilled-syringe-gains-positive-chmp-opinion?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/gsks-shingrix-prefilled-syringe-gains-positive-chmp-opinion?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4532","LU1829250122.USD","BK4087","GSK","GSK.UK","BK4585","BK4007","CHMP"],"gpt_icon":0},{"id":"2577895071","title":"Verrica Pharmaceuticals announces CHMP support for Ycanth MAA filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2577895071","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577895071?lang=en_us&edition=fundamental","pubTime":"2025-10-21 04:45","pubTimestamp":1760993112,"startTime":"0","endTime":"0","summary":"Verrica Pharmaceuticals (VRCA) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has provided feed...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/verrica-pharmaceuticals-announces-chmp-support-for-ycanth-maa-filing-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/verrica-pharmaceuticals-announces-chmp-support-for-ycanth-maa-filing-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CHMP","BK4588","BK4007","VRCA","BK4087","MAA","BK4215","BK4585"],"gpt_icon":0},{"id":"2577489352","title":"Verrica Pharmaceuticals Receives Positive Feedback from the European Medicines Agency (EMA) Supporting a Clear Regulatory Path Forward to File for Approval of YCANTH® in the European Union","url":"https://stock-news.laohu8.com/highlight/detail?id=2577489352","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577489352?lang=en_us&edition=fundamental","pubTime":"2025-10-21 04:05","pubTimestamp":1760990700,"startTime":"0","endTime":"0","summary":"– EMA concludes that the primary endpoint and supportive secondary endpoints from prior successful Phase 3 studies conducted in the U.S. and Japan are adequate to support a filing for the approval of ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/20/3169756/0/en/Verrica-Pharmaceuticals-Receives-Positive-Feedback-from-the-European-Medicines-Agency-EMA-Supporting-a-Clear-Regulatory-Path-Forward-to-File-for-Approval-of-YCANTH-in-the-European-.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCO","BK4588","BK4081","BK4215","BK4202","MAA","BK4087","BK4145","BK4585","CHMP","EMA","FORD"],"gpt_icon":0},{"id":"2577866044","title":"How Could EMA's Elfabrio Decision Reshape Protalix BioTherapeutics' (PLX) Rare Disease Strategy?","url":"https://stock-news.laohu8.com/highlight/detail?id=2577866044","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577866044?lang=en_us&edition=fundamental","pubTime":"2025-10-20 21:16","pubTimestamp":1760966206,"startTime":"0","endTime":"0","summary":"Earlier in October 2025, Protalix BioTherapeutics and Chiesi Group received a negative opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) regarding Elfabrio’s proposed less-frequent dosing regimen for Fabry disease, as the data was considered insufficient to demonstrate similar efficacy to the currently approved schedule.\nThis regulatory decision highlights ongoing challenges in achieving flexibility for rare disease treatments, with...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nysemkt-plx/protalix-biotherapeutics/news/how-could-emas-elfabrio-decision-reshape-protalix-biotherape","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nysemkt-plx/protalix-biotherapeutics/news/how-could-emas-elfabrio-decision-reshape-protalix-biotherape","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","EMA","BK4087","BK4081","CHMP","PLX"],"gpt_icon":0},{"id":"2576505793","title":"Why Is Protalix BioTherapeutics Stock Falling On Friday?","url":"https://stock-news.laohu8.com/highlight/detail?id=2576505793","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576505793?lang=en_us&edition=fundamental","pubTime":"2025-10-17 23:23","pubTimestamp":1760714580,"startTime":"0","endTime":"0","summary":"EMA issues a negative opinion on Protalix and Chiesi's Elfabrio revised dosing for Fabry disease, citing insufficient data to confirm efficacy.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/10/17/Medicine-And-Health-Concept--On-A-White-.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/10/17/Medicine-And-Health-Concept--On-A-White-.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/health-care/25/10/48278076/why-is-protalix-biotherapeutics-stock-falling-on-friday","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/25/10/48278076/why-is-protalix-biotherapeutics-stock-falling-on-friday","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["QURE","LU0109394709.USD","CHMP","PLX","BK4081","EMA","LU0320765992.SGD","LU0889565916.HKD","BK4087","BK4139"],"gpt_icon":0},{"id":"2576978030","title":"Agios Gets CHMP Backing of Pyrukynd in Thalassemia","url":"https://stock-news.laohu8.com/highlight/detail?id=2576978030","media":"Dow Jones","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576978030?lang=en_us&edition=fundamental","pubTime":"2025-10-17 20:36","pubTimestamp":1760704560,"startTime":"0","endTime":"0","summary":"Agios Pharmaceuticals said a key European regulatory committee has recommended expanded approval of its Pyrukynd anemia drug for certain people with the inherited blood disorder thalassemia.Agios on Friday said the recommendation by the European Medicines Agency's Committee for Medicinal Products for Human Use covers Pyrukynd in adults for the treatment of anemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassemia.The European Commission, which generally follows CHMP's advice, will now review the recommendation, with a decision expected by early next year, Agios said.The U.S. Food and Drug Administration is currently reviewing Pyrukynd in thalassemia, with a target action date of Dec. 7. The drug is already approved in the U.S. for the treatment of hemolytic anemia in adults with pyruvate-kinase, or PK, deficiency and in Europe for PK deficiency in adults.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGIO","CHMP","BK4139","BK4087"],"gpt_icon":0},{"id":"2576059714","title":"Agios’ PYRUKYND® (mitapivat) Receives Positive CHMP Opinion for Adults with Thalassemia","url":"https://stock-news.laohu8.com/highlight/detail?id=2576059714","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576059714?lang=en_us&edition=fundamental","pubTime":"2025-10-17 20:00","pubTimestamp":1760702400,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., Oct.  17, 2025  (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients w","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/17/3168588/31990/en/Agios-PYRUKYND-mitapivat-Receives-Positive-CHMP-Opinion-for-Adults-with-Thalassemia.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EMA","PK","IE00BLDYK493.USD","RBC","BK4081","IE00B64QTZ34.USD","LU2065731478.USD","CHMP","BK4181","BK4161","BK4087","BK4218"],"gpt_icon":0},{"id":"2576031359","title":"Novartis Scemblix receives positive CHMP opinion for Scemblix","url":"https://stock-news.laohu8.com/highlight/detail?id=2576031359","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576031359?lang=en_us&edition=fundamental","pubTime":"2025-10-17 18:55","pubTimestamp":1760698518,"startTime":"0","endTime":"0","summary":"Novartis (NVS) announced that the Committee for Medicinal Products for Human Use, CHMP, of the European Medicines Agency, EMA, has adopted a positi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/novartis-scemblix-receives-positive-chmp-opinion-for-scemblix-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/novartis-scemblix-receives-positive-chmp-opinion-for-scemblix-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE0002141913.USD","IE00B4R5TH58.HKD","BK4578","BK4588","BK4007","IE00BJT1NW94.SGD","LU0208291251.USD","IE00BFTCPJ56.SGD","BK4532","BK4585","IE0009355771.USD","LU0320765489.SGD","BK4087","CHMP","NVS","LU0070302665.USD","LU0211331839.USD","IE00B2B36J28.USD","IE00BJJMRZ35.SGD"],"gpt_icon":0},{"id":"2576703191","title":"Novartis Scemblix® receives positive CHMP opinion for the treatment of adults with newly diagnosed CML","url":"https://stock-news.laohu8.com/highlight/detail?id=2576703191","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576703191?lang=en_us&edition=fundamental","pubTime":"2025-10-17 18:37","pubTimestamp":1760697420,"startTime":"0","endTime":"0","summary":"If approved, Scemblix will be indicated for adults with chronic myeloid leukemia (CML), both newly diagnosed and previously treated, expanding access to four times as many patients in EuropeScemblix i","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/17/3168516/0/en/Novartis-Scemblix-receives-positive-CHMP-opinion-for-the-treatment-of-adults-with-newly-diagnosed-CML.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4081","IMA","EC","BK4087","EMA","BK4201","CHMP","BK4007"],"gpt_icon":0},{"id":"2576977086","title":"CStone Pharmaceuticals Gains CHMP Positive Opinion for Sugemalimab in Stage III NSCLC","url":"https://stock-news.laohu8.com/highlight/detail?id=2576977086","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576977086?lang=en_us&edition=fundamental","pubTime":"2025-10-17 08:09","pubTimestamp":1760659773,"startTime":"0","endTime":"0","summary":"CStone Pharmaceuticals ( ($HK:2616) ) has shared an announcement. CStone Pharmaceuticals announced that the European Medicines Agency’s Committee f...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cstone-pharmaceuticals-gains-chmp-positive-opinion-for-sugemalimab-in-stage-iii-nsclc?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cstone-pharmaceuticals-gains-chmp-positive-opinion-for-sugemalimab-in-stage-iii-nsclc?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4087","BK4134","III","SSI","CHMP"],"gpt_icon":0},{"id":"2573067947","title":"Cellectar Biosciences Announces European Medicines Agency (EMA) Confirms Eligibility to File for Conditional Marketing Authorization (CMA) for Iopofosine I 131 as a Treatment for Refractory (post-BTKi) Waldenstrom Macroglobulinemia (WM)","url":"https://stock-news.laohu8.com/highlight/detail?id=2573067947","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573067947?lang=en_us&edition=fundamental","pubTime":"2025-10-06 19:00","pubTimestamp":1759748400,"startTime":"0","endTime":"0","summary":"Following Scientific Advice and Guidance from Scientific Advice Working Party (SAWP) of EMA, Submission of CMA Application for Iopofosine I 131 as a Treatment for Refractory (post-BTKi) WM Expected in","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/06/3161577/29076/en/Cellectar-Biosciences-Announces-European-Medicines-Agency-EMA-Confirms-Eligibility-to-File-for-Conditional-Marketing-Authorization-CMA-for-Iopofosine-I-131-as-a-Treatment-for-Refra.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4567","BK4566","LU2125910179.SGD","BK4079","LU0069063385.USD","COMP","LU0868494708.USD","LU0057025933.USD","BK4589","LU1923621640.USD","LU2362541273.HKD","WM","LU1430594728.SGD","LU2238339852.HKD","LU2413666699.HKD","CLRB","BK4520","BK4516","LU2463526074.USD","LU0511384066.AUD","LU0942090050.USD","LU1988902786.USD","LU2092937221.SGD","ORR","LU1989772923.USD","LU1623119135.USD","MDCO","CHMP","LU2362541513.USD","LU2229751404.USD","LU1585245621.USD","LU1989772840.SGD","LU2362540622.SGD","LU2125910336.SGD","BK4533","BK4534","BK4120","LU2264538146.SGD","EMA","CMA","PDCO","CAT","LU2237438978.USD","PRAC","IE00BD6J9T35.USD","LU2089279066.USD","CNS","LU1064131342.USD","LU1712237335.SGD","IE00BSNM7G36.USD"],"gpt_icon":0},{"id":"2570404407","title":"Crinetics Announces FDA Approval of PALSONIFY™ (paltusotine) for the Treatment of Adults with Acromegaly","url":"https://stock-news.laohu8.com/highlight/detail?id=2570404407","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570404407?lang=en_us&edition=fundamental","pubTime":"2025-09-26 05:30","pubTimestamp":1758835800,"startTime":"0","endTime":"0","summary":"Palsonify Pills   Palsonify pills   Palsonify Logo   Palsonify tablets    Crinetics Exterior   Crinetics headquarters in San Diego, CA  Novel nonpeptide SST2 agonist PALSONIFY advances the treatment p","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/09/25/3156767/0/en/Crinetics-Announces-FDA-Approval-of-PALSONIFY-paltusotine-for-the-Treatment-of-Adults-with-Acromegaly.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4087","BK4215","SKK","BK4585","BK4129","CHMP","MAA"],"gpt_icon":0},{"id":"2569865759","title":"Clinuvel Pharmaceuticals Says EMA Removes Recommended Maximum Dose for Genetic Disorder Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2569865759","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569865759?lang=en_us&edition=fundamental","pubTime":"2025-09-23 07:52","pubTimestamp":1758585135,"startTime":"0","endTime":"0","summary":"Clinuvel Pharmaceuticals (ASX:CUV) said the European Medicines Agency (EMA) agreed to amend the label for Scenesse, or afamelanotide, removing the recommended maximum annual dose of four implants per ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4087","EMA","BK7067","BK4081","CUV.AU","CHMP","BK7508"],"gpt_icon":0},{"id":"2569376647","title":"Sanofi’s Dupixent Advances in EU with Positive CHMP Opinion","url":"https://stock-news.laohu8.com/highlight/detail?id=2569376647","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569376647?lang=en_us&edition=fundamental","pubTime":"2025-09-23 03:17","pubTimestamp":1758568645,"startTime":"0","endTime":"0","summary":"An announcement from Sanofi ( ($SNY) ) is now available. On September 22, 2025, Sanofi and Regeneron announced that their drug Dupixent received a ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/sanofis-dupixent-advances-in-eu-with-positive-chmp-opinion?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/sanofis-dupixent-advances-in-eu-with-positive-chmp-opinion?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4087","CHMP","SNYNF","BK4007","BK4156"],"gpt_icon":0},{"id":"2569732665","title":"European Advisory Panel Recommends Two AstraZeneca Drugs For Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2569732665","media":"Benzinga","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569732665?lang=en_us&edition=fundamental","pubTime":"2025-09-23 02:20","pubTimestamp":1758565200,"startTime":"0","endTime":"0","summary":"AstraZeneca and Amgen secure CHMP support for Tezspire in nasal polyps and Koselugo in neurofibromatosis after strong Phase 3 trial results.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/09/22/Konskie--Poland---January-03--2024-Astra.jpeg?optimize=medium&dpr=2&auto=webp&width=260","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/09/22/Konskie--Poland---January-03--2024-Astra.jpeg?optimize=medium&dpr=2&auto=webp&width=260"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/markets/large-cap/25/09/47801834/european-advisory-panel-recommends-two-astrazeneca-drugs-for-approval","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/large-cap/25/09/47801834/european-advisory-panel-recommends-two-astrazeneca-drugs-for-approval","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["BK4096","CHMP","ORR","BK4156","BK4081","EMA","BK4087"],"gpt_icon":0},{"id":"2569739255","title":"Dr. Reddy’s Receives Positive CHMP Opinion for AVT03 Biosimilar","url":"https://stock-news.laohu8.com/highlight/detail?id=2569739255","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569739255?lang=en_us&edition=fundamental","pubTime":"2025-09-23 00:23","pubTimestamp":1758558182,"startTime":"0","endTime":"0","summary":"Dr Reddy’s Laboratories ( ($RDY) ) has shared an update. On September 22, 2025, Dr. Reddy’s Laboratories announced that the European Medicines Agen...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/dr-reddys-receives-positive-chmp-opinion-for-avt03-biosimilar?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/dr-reddys-receives-positive-chmp-opinion-for-avt03-biosimilar?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CHMP","BK4087"],"gpt_icon":0},{"id":"2569082062","title":"Dupixent® (dupilumab) to Treat Chronic Spontaneous Urticaria (CSU) Advances in EU with Positive CHMP Opinion","url":"https://stock-news.laohu8.com/highlight/detail?id=2569082062","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569082062?lang=en_us&edition=fundamental","pubTime":"2025-09-22 12:29","pubTimestamp":1758515340,"startTime":"0","endTime":"0","summary":"Recommendation for adults and adolescents based on Phase 3 trials showing Dupixent significantly reduced itch and hives at 24 weeks compared to placebo If approved, Dupixent would be the first targete","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/09/22/3153615/0/en/Dupixent-dupilumab-to-Treat-Chronic-Spontaneous-Urticaria-CSU-Advances-in-EU-with-Positive-CHMP-Opinion.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2362540622.SGD","LU0823416689.USD","LU0114720955.EUR","BK4096","IE00BFXG1179.USD","LU0053666078.USD","LU0072461881.USD","REGN","LU0320765646.SGD","LU2362541273.HKD","LU1162221912.USD","CHMP","LU0882574055.USD","LU1917777945.USD","LU2237438978.USD","LU1974910355.USD","BK4156","BK4585","LU0109394709.USD","LU0289739699.SGD","LU2362541513.USD","SNY","LU0823434740.USD","LU2023250504.SGD","BP","LU0058720904.USD","LU0320765992.SGD","LU1829250122.USD","BK4007","BK4588","LU2089984988.USD","BK4087","LU0162691827.USD","LU2106854487.HKD","LU2468319806.SGD","LU0889565916.HKD","BK4201","BK4139","LU0823434583.USD"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":3,"totalSize":62,"code":"91000000","status":"200"}]}}